Drug Trial Radar · NCT02307682
Efficacy and Safety of RTH258 Versus Aflibercept - Study 1
Last checked: Nov 20, 2026Latest source record: Jan 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,775
Actual
Start
Dec 8, 2014
Primary completion
Apr 22, 2017
Study completion Mar 28, 2018
Sponsor
- Lead sponsor
- Alcon ResearchIndustry
- Sponsor type
- Industry
- First posted
- Dec 4, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare brolucizumab (RTH258) ophthalmic solution for intravitreal (IVT) injection at two dosage levels (3 mg and 6 mg) to aflibercept ophthalmic solution for IVT injection (2 mg) in subjects with untreated active choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) in the study eye.
Conditions
- Neovascular Age-Related Macular Degeneration
- Choroidal Neovascularization
Interventions
Brolucizumab ophthalmic solutionDrug
Ophthalmic solution for IVT injection
Aflibercept ophthalmic solutionDrug
Ophthalmic solution for IVT injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Best Corrected Visual Acuity (BCVA) (Letters Read) at Week 48 - Study EyeTime frame: Baseline, Week 48
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Contact Alcon Call Center for Trial Locations
Fort Worth, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.